Company ProfilePremium

Advance ZincTek Limited (formerly Advance NanoTek Limited)

Company Profile Analysis

Ticker: ANO.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Advance ZincTek Limited - Company showcase

Year Founded & Workforce

1997

25 Employees

Advance ZincTek Limited logo

Advance ZincTek Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Advance ZincTek Limited Overview

Advance ZincTek is a vertically integrated Australian specialty-materials manufacturer. Its core product is high-transparency, pharmaceutical-grade zinc oxide sold under the ZinClear brand, both as powders (ZinClear XP) and as ready-to-formulate dispersions in natural emollients. These are used as broad-spectrum "mineral" UV filters in sunscreens, cosmetics and topical pharmaceuticals. It also makes plate-like alumina effect powders (Alusion, rebranded White Sapphire) for colour cosmetics and is developing magnesium oxide and other cosmetic oxides. It operates from a TGA-licensed, solar-assisted facility in Brisbane and sells mainly through distributors. North America (US and Canada) generated 57% of FY2026 revenue. The investment case rests on the regulatory shift away from organic chemical UV filters (oxybenzone, homosalate, 4-MBC) toward mineral filters. Offsetting this are customer concentration, controlling-shareholder governance, US FDA compliance overhang, very slow inventory turnover, and a newly announced, unproven diversification into home battery storage.


Company's own description (latest Annual Report, FY2026)

The FY2026 Directors' Report describes the principal continuing activities as predominantly the manufacture of aluminium oxide powder (Alusion), zinc oxide dispersions and zinc oxide powder, collectively branded ZinClear, for the Personal Care Sector. It reports no significant change in the nature of activities. The operating-segment note (Note 23) identifies one reportable segment, Personal Care. That segment produces and distributes dispersions of mineral-only UV filters in cosmetic emollients for sunscreen, skincare and pharmaceutical formulations, plus alumina plate-like powders for cosmetic applications. The Corporate Governance Statement frames the Board's objective as creating long-term shareholder value through diversified product sales and development in cosmetics and sunscreen.

Independent characterisation

ANO is best understood as a niche active-pharmaceutical-ingredient (API) and cosmetic-ingredient manufacturer. It sits in the upstream-to-midstream part of the personal-care value chain:

  1. Inputs. It buys raw zinc oxide feedstock and other raw materials from overseas suppliers, sometimes paying deposits in advance (FY2026 AR Note 11: A$172k of supplier deposits). It also buys carrier oils, many of them organic or vegan certified.

  2. Conversion. It applies proprietary particle-engineering and dispersion know-how, which originated in mechanochemical processing research at the University of Western Australia and was scaled up through a 2000–2004 joint venture with Samsung Corning. The result is transparent, low-whitening zinc oxide powders and high-load dispersions (50% and 65% w/w zinc oxide grades are FDA NDC-listed).

  3. Distribution. It sells through a network of specialty-chemical distributors in the US/Canada, Europe and Asia. In the US it moved from one exclusive distributor to four non-exclusive distributors during FY2024–FY2025. In Australia it also sells directly to contract sunscreen manufacturers.

  4. Downstream (limited). It sells finished sunscreen products, mainly to the related party Veganic SKN Limited, and holds capitalised "ZinXation" end-formulation assets. Through a subsidiary established in FY2023, Sunscreen Safety Testing Laboratory Pty Ltd, it offers in-house SPF and safety testing support.

Business and revenue model

Revenue model elementAssessment
Product vs service vs subscription vs licensingAbout 100% product sales recognised at a point in time (AASB 15, FY2026 AR Note 5). No subscription revenue. Licence income was historically recognised (FY2023 accounting policy) but nothing material has been reported since. Testing services via SSTL are not separately disclosed
PricingNot publicly disclosed. Management states it adjusts selling prices for FX movements (no hedging). The FY2023 AR said EcoZinc launched at "increased pricing levels"
Customer typeB2B: specialty-chemical distributors, contract sunscreen manufacturers, cosmetic brand owners. Related-party B2B: Veganic SKN Limited (sunscreen products, A$1.28m in FY2026)
Customer concentrationFY2026: three customers at 23.97%, 20.4% and 11.78% of revenue (about 56% combined). FY2025: four customers at more than 11% each, 65% combined. FY2024: three customers, 50% (Note 23(b))
End-marketsSunscreen (OTC drug in US/Australia; cosmetic in EU), daily-wear skincare with SPF, colour cosmetics (alumina effect pigments), topical pharmaceuticals (zinc oxide as skin protectant). Management has identified adjacent agricultural, textile and rubber markets (FY2023 AR) and now home battery storage (FY2026 AR)
Geographic mix FY2026USA & Canada 57.2%; Australia 23.0%; Europe 10.8%; Rest of world 9.0%

Value-chain position and moat sources

The defensible elements are (i) regulatory licences, namely Australian TGA manufacturing licensing and US FDA drug-establishment registration and NDC listings, which are costly and slow for new entrants to obtain; (ii) particle-dispersion know-how protected partly by patents ("Patented Dispersions" development asset, A$1.2m net book value at FY2026); and (iii) a "clean label" positioning (organic and vegan carrier oils, solar-powered "EcoZinc"). The main weaknesses are scale (about A$13m revenue against multinational competitors), dependence on a few distributors, and the commoditisation risk from lower-priced Asian zinc oxide imports, which management has publicly described as non-compliant in the Australian market (ASX release, 2 Oct 2025).

Strategy

Stated strategic themes (FY2025–FY2026 ARs, AGM Nov 2025), paraphrased

  1. Grow distribution breadth, particularly non-exclusive multi-distributor models. Examples are the US move from 1 to 4 distributors and entry into countries where ANO is not represented (AGM 2025).

  2. Ride regulatory displacement of chemical UV filters. Management actively campaigns on the health and environmental risks of oxybenzone, avobenzone, homosalate and 4-MBC, including LinkedIn campaigns reporting more than 8.2 million impressions (FY2025 AR). The FY2026 AR tabulates 4-MBC bans across the EU, UK, China, ASEAN, East Africa and Central America.

  3. Embed AI across the business (sales analytics, formulation development, training). The company claims shorter development cycles and stable wages despite CPI (FY2025 and FY2026 Chairman's Letters).

  4. Product diversification into adjacent oxides: High Purity White Sapphire, magnesium oxide, three new cosmetic oxides.

  5. Operational efficiency: Perth closure, Brisbane consolidation, ERP/CRM implementation scheduled FY2026 (CRM, bill of materials, workflow scheduling, project management).

  6. Supply-chain resilience: higher US stock against tariffs, possible build-up of key raw materials (FY2026 MD review), and a stated willingness to relocate production to the USA if tariffs required it (9 Jul 2025 release).

  7. New growth vector — home battery storage (FY2027–FY2028). A pilot facility and equipment in FY2027, a pilot battery for testing in FY2028, using zinc oxide and high-purity alumina (ceramic separator coatings).

Strategic initiatives register (last 24 months)

InitiativeAnnouncedTargets / metrics disclosedStatus (Oct 2026)
End US/Canada distributor exclusivity; 4 distributorsFY2024 Board decision (FY2025 AR)US sales A$2.54m → A$6.15m (FY2025) → A$7.50m (FY2026)Delivered
Perth facility and office closureFY2024 decision; AGM Nov 2025About A$750k savings FY2025; further savings FY2026Delivered
White Sapphire Matte/Glow relaunchFY2025More than 200 samples; test orders receivedRevenue still declining (A$111k FY2026)
High Purity White SapphireFY202516+ applications; 600+ potential customers; launch 2026Development; not launched per FY2026 AR
Magnesium oxideFY2025Marketing FY2026No revenue disclosed
Three new cosmetic oxidesFY2025TrialsDevelopment
AI adoptionFY2025QualitativeOngoing
ERP/CRM softwareFY2025Implementation FY2026Not reported as complete
Capital management (2c capital return)Jun 2025 flagged; Feb 2026 executedA$1.226mCompleted 25 Feb 2026
Raw-material stock buildFY2026 ARNot quantifiedUnder Board consideration
Home battery storageFY2026 AR (31 Aug 2026)Pilot facility FY2027; prototype FY2028Pre-development; no capex budget disclosed
Sustainability (PV, organic/vegan inputs, EcoZinc)FY2023 onward50% of FY2023 production on PV powerOngoing; no formal targets

Medium-term financial targets / guidance

ANO does not publish medium-term financial targets. Its only quantitative guidance has been short-dated, unaudited pre-announcements:

  • 10 Jun 2025: expected FY2025 PBT of about A$1.95m (the "A$2.7m turnaround"); actual was A$2.024m.

  • 20 Jul 2026: FY2026 unaudited PBT A$2.294m; audited A$2.247m, 2% lower.

The standing forward-looking statement in each AR is only that the Group has a solid platform from which to grow sales, improve margins and deliver profitability.

Products & Services

All products sit within the single Personal Care segment. Pricing is not publicly disclosed for any line.

Product Portfolio

Product / brandDescription & key specificationsTarget customerLaunch / latest versionStatus & notes

ZinClear XP (powder)

High-transparency, pharmaceutical-grade zinc oxide powder used as a broad-spectrum UVA/UVB mineral filter. Shelf life extended from 3 to 5 years (FY2023 AR). FDA NDC listing shows 100% zinc oxide powder (labeler code 83679)

Sunscreen and cosmetics formulators, contract manufacturers

Long-standing; 5-year shelf life from FY2023

Core product. Manufacturing cost of XP powder cut 15% in FY2023

ZinClear dispersions

Pre-dispersed zinc oxide in cosmetic emollients. FDA NDC listings for 50% w/w and 65% w/w zinc oxide "solutions" in pack sizes from 1 kg bottles to 200 kg drums and 1,260 kg containers (openFDA via HelloPharmacist). Carrier oils include sunflower and coconut variants (development-asset names, FY2023 AR); expansion to five organic/vegan base oils planned (FY2023 AR)

Brand owners wanting easy-to-formulate, low-whitening mineral sunscreens; organic/vegan brands

Ongoing; new oil bases FY2024–25

Core product. Capitalised "Patented Dispersions" asset A$1.42m cost

EcoZinc

Premium ZinClear grade manufactured "100% powered by the sun" using on-site PV (FY2023 AR)

Sustainability-positioned brands

Launched FY2023/FY2024

Sold at premium pricing via distributors (per company)

ZinXation

End-formulation (finished sunscreen) technology and recipes; capitalised development asset (A$783k cost; A$604k net, FY2026)

Australian contract manufacturers; brand owners; Veganic SKN

Original formulations before FY2018; asset additions FY2025

Linked to sunscreen product sales

Finished sunscreen products

Zinc-based sunscreen formulations supplied finished, mainly to Veganic SKN Limited (related party)

Related-party brand owner; selected third parties

Material from FY2023

FY2026 revenue A$1.463m

Alusion / White Sapphire (Glow, Matte)

Plate-like alumina (aluminium oxide) effect powders for colour cosmetics. "Matte" and "Glow" variants; more than 200 samples distributed in early 2025 (FY2025 AR)

Colour cosmetics manufacturers (Asia, Europe)

Alusion legacy; White Sapphire Matte/Glow 2025

Revenue collapsed after Sapphire Matte problem (Apr 2025)

High Purity White Sapphire

High-purity alumina. More than 16 potential applications identified, 3 requiring TGA-licensed manufacturing; addressable base of 600+ potential customers (company claim, FY2025 AR). Also targeted as ceramic separator coating for batteries (FY2026 AR)

Cosmetics, pharma, battery materials

Trials July 2025 needed refinement; launch targeted 2026 (AGM Nov 2025)

Development stage

Magnesium oxide

Cosmetic/pharma-grade MgO; trials successful, marketing to begin FY2026 (FY2025 AR)

Existing ZinClear customers

FY2026

No revenue separately disclosed

Three new cosmetic oxides

Raw-material sourcing for trials begun FY2025; aimed only at the cosmetic sector, to complement ZinClear

Cosmetic formulators

Development

Not named

Sunscreen Safety Testing Laboratory (SSTL)

Testing centre for ZinClear-based products (opened about Sep 2023 per FY2023 AR plan)

Customers formulating with ZinClear

FY2024

No separate revenue disclosed

Formulation support / dermatologist endorsement programme

Formulation recipes using ZinClear XP; access to endorsement by a named Queensland dermatologist (FY2023 AR Board initiatives)

Brand owners

FY2024–25

Marketing service, not separately monetised

Industrial zinc oxide (exploratory)

Agricultural, textile and rubber applications. Company sizes these US markets at about US$800m combined, against about US$600m for US pharmaceutical-grade zinc oxide (FY2023 AR, company estimate)

Industrial distributors

Exploratory since FY2023

No disclosed revenue

Residential battery energy storage (planned)

Full-process pilot from electrode slurry to battery pack, using zinc oxide and high-purity alumina expertise; pilot facility construction and equipment ordering in FY2027; prototype battery testing in FY2028 (FY2026 AR)

Home energy storage market

Announced Aug 2026

Pre-development; no budget disclosed

Financial Narrative

Sources: audited Annual Reports FY2022–FY2026 (FY2022 figures from FY2023 AR comparatives; FY2024 from FY2025 AR comparatives). Currency A$k unless stated.

Income statement

Notes: EBITDA = PBT + depreciation (PP&E and ROU) + amortisation + lease interest + finance costs. EBIT = PBT + interest expense. Both include other income (R&D tax incentive, FX gains and the FY2022 A$831k related-party IP sale gain). FY2023 shows both "lease interest" (A$110k) and "finance costs" (A$102k) on the face of the P&L; both are added back as reported. Tax expense is almost entirely deferred (non-cash) because of carried-forward losses.

Margins and growth

Revenue CAGR. FY2022→FY2026 (4 years): +1.2% p.a. FY2021→FY2026 (5 years, from the A$6.52m trough): +15.0% p.a. FY2020 (A$17.97m peak)→FY2026: –5.1% p.a. The starting point drives the answer: ANO has not regained its FY2020 revenue peak.

Balance sheet (30 June)

FY2024 borrowings of A$320k were an interest-free, on-demand loan from an entity associated with Lev Mizikovsky, repaid in FY2025 (FY2025 AR Note 26). The company states it has no external debt.

Cash flow

The FY2026 cash-flow statement labels the A$1.226m outflow "Payments from shares buyback", but the equity note and Directors' Report describe it as a 2-cent-per-share return of capital approved by shareholders. The analyst treats it as a capital return; no shares were cancelled (share count rose by 33,750 employee shares).

Ratio analysis

Invested capital = equity + lease liabilities + borrowings − cash. DIO uses "raw materials and consumables used" as a cost-of-goods proxy. Because labour and overheads are absorbed into inventory, true COGS is higher and true DIO somewhat lower, but the order of magnitude (more than 2 years of stock) is robust.

Commentary on trends, inflections and drivers

Revenue: cyclical, distributor-driven, not yet structurally growing. Revenue has moved in a "boom–bust–recovery" pattern driven by distributor ordering rather than end-demand. The FY2020 peak (A$18.0m) reflected heavy distributor stocking. FY2021 collapsed to A$6.5m as that stock unwound. FY2022–FY2023 recovered to A$12.5–13.7m, but FY2023 included an A$533k timing benefit: a US distributor bought stock in June 2022 on deferred terms (FY2023 AR "Adjusted Results"). FY2024 fell 32% to A$9.3m, with US/Canada down 62%. The Board's response, ending US exclusivity and moving to four distributors, drove a 141% US rebound in FY2025 and a further 23% in FY2026. FY2026 revenue (A$13.1m) is still 4.6% below FY2023 and 27% below FY2020. Management itself warned in FY2023 that disclosed sales orders were an unreliable forward indicator and stopped publishing them.

Gross margin: resilient and improving. Derived gross margin of 58–61% in four of five years points to genuine pricing power for pharmaceutical-grade transparent zinc oxide. The FY2023 Chairman noted stable gross margins without price increases, and FY2026 reached 60.8%. The FY2024 dip to 48.5% reflects under-absorption on lower volumes and the White Sapphire issue. Because labour and overheads are capitalised into inventory, the "raw materials used" line understates full COGS. Third-party aggregators report a different cost of revenue for FY2024 (A$8.47m per Kalkine/Stoxray data), which suggests they include absorbed overheads or inventory movements. Figures are not directly comparable.

Operating leverage and cost reset. Closing the Perth (Welshpool) facility and consolidating in Brisbane saved about A$750k in FY2025 (Chairman's Letter). PP&E depreciation has been flat at about A$1.2m. In FY2026, operating cost lines grew faster than revenue: corporate costs rose from A$171k to A$469k, consulting from A$120k to A$262k, other operating expenses from A$584k to A$1,109k (including a A$289k FX loss), and superannuation by 32%. As a result, EBITDA margin slipped from 32.9% to 31.3% despite gross-margin expansion. Part of the cost growth plausibly relates to FDA remediation and US regulatory work, but the AR does not attribute it.

Earnings quality. About 90% of the gap between EBITDA and NPAT is non-cash depreciation and deferred tax. ANO pays no cash income tax because of A$4.69m of tax-effected carried-forward losses (FY2026 Note 15). Other income (R&D incentive of about A$0.5m a year) is about 22% of PBT in FY2026, so underlying operating profit is lower than headline PBT suggests. The H1/H2 split is also notable. H1 FY2026 NPAT was A$1,158k (Appendix 4D), leaving only A$351k for H2 on revenue of A$6,449k. That points to H2 cost pressure (FX loss, consultants, inventory provision increase of A$132k).

Balance sheet: asset-heavy, cash-light. Equity of A$36m is dominated by inventory (A$11.3m), PP&E (A$11.3m) and deferred tax assets (A$5.4m). Cash has been below A$1.4m at every year-end in the window, and only A$0.6m at FY2026. That is unusually thin for a company that also returned A$1.2m of capital and is announcing a battery pilot plant. Liquidity rests on receivables and the ability to slow inventory production. There is no external debt facility disclosed.

Inventory: the central analytical issue. Inventory of A$11.3m is equivalent to about 0.86x annual revenue and, on raw-material cost, more than two years of consumption. The auditor has flagged inventory valuation and existence as a key audit matter in every year reviewed. Management justifies elevated stock by (a) faster delivery than competitors, (b) holding stock in the US to pre-empt tariffs, and (c) potential raw-material shortages. In the FY2026 AR the Board said it may divert "excess cash" to increasing raw-material stocks, which is hard to reconcile with a A$0.6m cash balance. The FY2026 provision for impairment more than doubled to A$235k. Any NRV reassessment, product shelf-life issue or regulatory restriction on US sales would therefore hit equity directly.

Cash flow. OCF has been positive every year and reached a five-year high of A$3.35m in FY2026, helped by inventory drawdown (A$573k) and prepayment unwinds. After PP&E capex, capitalised development and lease principal, discretionary free cash flow was about A$1.2m in FY2026. That roughly matches the capital return, which explains why year-end cash was unchanged.

Capital efficiency is weak. ROE of 4–7% in good years and ROIC around 4–5% sit well below any reasonable cost of equity for an illiquid micro-cap. The persistent gap between NAV per share (57.5c) and share price (71–80c) is modest, but the market is clearly not paying for growth.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryOwnershipFunction (analyst characterisation)

Advance ZincTek Limited

Australia

Parent

Listed head entity; manufacturing; TGA/FDA licence holder

Antaria Pty Ltd

Australia

100%

Legacy operating subsidiary (former Antaria brand)

Sunscreen Safety Testing Laboratory Pty Ltd

Australia

100% (established FY2023)

SPF/safety testing support for ZinClear-based formulations

Antaria, Inc

USA

100%

US commercial entity; Dallas TX warehouse

Antaria Europe, B.V.

Netherlands

100%

EU commercial entity; s'Heerenberg third-party warehouse (Mainfreight)

Product Lines

Product line (AUD K)FY2022FY2023FY2024FY2025FY2026

ZinClear zinc oxide powders & dispersions (AUD K)

11,45611,8927,83011,10011,537

Alusion / White Sapphire alumina (AUD K)

9839451,020150111

Sunscreen products (AUD K)

659084703891,463

Total revenue (AUD K)

12,50413,7459,32011,63913,111

Revenue by Segment (%) and Segment Margins & Growth (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

ZinClear share of revenue (%)

91.686.584.095.488.0

Alusion/White Sapphire share of revenue (%)

7.96.910.91.30.8

Sunscreen products share of revenue (%)

0.56.65.03.311.2

ZinClear YoY growth (%)

03.8-34.241.83.9

Alusion/White Sapphire YoY growth (%)

0-3.97.9-85.3-26.0

Sunscreen products YoY growth (%)

01,297-48.2-17.2276

Revenue by Segment and Segment Margins & Growth (%)

Metric (AUD K unless %)FY2022FY2023FY2024FY2025FY2026

Segment (= group) revenue (AUD K)

12,50413,7459,32011,63913,111

Segment (= group) profit before tax (AUD K)

3,6822,291-9902,0242,247

Segment PBT margin (%)

29.416.7-10.617.417.1

Revenue YoY growth (%)

91.79.9-32.224.912.6

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

12,50413,7459,32011,63913,111

Other income incl. R&D incentive (AUD K)

1,750895684676643

Raw materials & consumables (AUD K)

5,1665,6774,8014,9275,145

Gross profit, derived = revenue less raw materials (AUD K)

7,3388,0684,5196,7127,966

Employee benefits incl. super (AUD K)

1,8682,6711,8361,8941,996

Depreciation PP&E (AUD K)

9991,1961,2621,2061,200

Depreciation right-of-use (AUD K)

495509513456425

Amortisation (AUD K)

66716291180

Interest expense, lease + finance (AUD K)

204212895652

EBITDA, derived (AUD K)

5,4464,2799363,8334,104

EBITDA excluding other income, derived (AUD K)

3,6963,3842523,1573,461

EBIT / operating income, derived (AUD K)

3,8862,503-9012,0802,299

Profit before tax (AUD K)

3,6822,291-9902,0242,247

Income tax expense (benefit) (AUD K)

1,491628-87786738

Net profit after tax (AUD K)

2,1911,663-9031,2381,509

Basic EPS (A$ cents)

3.582.69-1.451.982.41

Diluted EPS (A$ cents)

3.582.69-1.451.982.41

Weighted avg shares (millions)

61.2261.6262.4562.5062.65

Dividends paid per share in year (A$ cents)

06000

Capital return per share (A$ cents)

00002

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

91.79.9-32.224.912.6

Gross margin, derived (%)

58.758.748.557.760.8

EBITDA margin (%)

43.631.110.032.931.3

EBITDA margin excl. other income (%)

29.624.62.727.126.4

EBIT margin (%)

31.118.2-9.717.917.5

PBT margin (%)

29.416.7-10.617.417.1

Net margin (%)

17.512.1-9.710.611.5

Income Statement

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

4,1485,0976,58412,26017,9676,52312,50413,7459,32011,63913,111

Profit before tax (AUD K)

-4525611,1253,3817,4612653,6822,291-9902,0242,247

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

38,26839,06237,74138,04037,815

Cash & equivalents (AUD K)

1,331325163629618

Trade & other receivables (AUD K)

4,4393,8332,3583,2774,256

of which trade receivables, gross (AUD K)

4,0172,6211,0912,1483,028

Inventories (AUD K)

10,89113,06612,73411,88711,314

Property, plant & equipment (AUD K)

10,47812,00411,94111,61711,329

Right-of-use assets (AUD K)

2,3822,0001,4871,235866

Deferred tax assets (AUD K)

5,5145,3415,9435,6525,410

Development assets / intangibles (AUD K)

1,9431,9752,6693,1143,671

Goodwill (AUD K)

00000

Short-term debt incl. current leases (AUD K)

454513735418513

Long-term debt, non-current leases (AUD K)

2,0841,6651,250983357

Total debt incl. leases (AUD K)

2,5382,1781,9851,401870

Bank / related-party borrowings (AUD K)

0032000

Net debt incl. leases (AUD K)

1,2071,8531,822772252

Net debt excl. leases (AUD K)

-1,331-325157-629-618

Total liabilities (AUD K)

3,2793,7793,3612,2711,760

Total equity (AUD K)

34,98935,28334,38035,76936,055

Working capital (AUD K)

16,94715,85413,68815,21415,245

Net assets per share (A$ cents)

57.0656.5055.0557.0957.52

Net tangible assets per share (A$ cents)

45.1545.0841.5543.3643.03

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

1,6194,4212,2392,6753,345

Capex, PP&E (AUD K)

2,4932,7371,451887933

Capitalised development spend (AUD K)

71575757536736

Lease principal repayments (AUD K)

458514513466491

Free cash flow = OCF less PP&E capex (AUD K)

-8741,6847881,7882,412

Free cash flow after development & leases (AUD K)

-2,0471,095-4827861,185

Dividends paid in cash (AUD K)

01,420000

Capital return paid (AUD K)

00001,226

Share buybacks (AUD K)

00000

Equity raised (AUD K)

2,4420000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

7.04.7-2.63.54.2

ROA on closing assets (%)

5.74.3-2.43.34.0

ROIC, NOPAT at 30% over invested capital (%)

7.54.7-1.74.04.4

Current ratio (x)

17.99.47.813.612.8

Debt incl. leases to equity (x)

0.070.060.060.040.02

Net debt incl. leases to EBITDA (x)

0.220.431.950.200.06

Interest coverage, EBIT over interest (x)

19.011.8-10.137.144.2

Asset turnover, revenue over closing assets (x)

0.330.350.250.310.35

Days inventory outstanding, on raw materials used (days)

769840968881803

Days sales outstanding, trade receivables (days)

11770436784

Days payables outstanding, trade payables (days)

3071723434

Cash conversion cycle (days)

856839939914853

Revenue by Region

Region (AUD K)FY2022FY2023FY2024FY2025FY2026

Australia (AUD K)

1,5952,5031,6752,2113,013

United States & Canada (AUD K)

7,5946,7232,5396,1157,495

Europe (AUD K)

2,2472,4592,7721,0561,421

Rest of world, mainly Asia (AUD K)

1,0682,0602,3342,2571,182

Total (AUD K)

12,50413,7459,32011,63913,111

Region Margins & Growth (%) and Revenue by Region (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Australia YoY growth (%)

056.9-33.132.036.3

US & Canada YoY growth (%)

0-11.5-62.2140.822.6

Europe YoY growth (%)

09.412.7-61.934.6

Rest of world YoY growth (%)

092.913.3-3.3-47.6

Australia share (%)

12.818.218.019.023.0

US & Canada share (%)

60.748.927.252.557.2

Europe share (%)

18.017.929.79.110.8

Rest of world share (%)

8.515.025.019.49.0

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

2.021.770.720.830.80

Net assets per share (A$ cents)

57.0656.5055.0557.0957.52

NTA per share (A$ cents)

45.1545.0841.5543.3643.03

Basic EPS (A$ cents)

3.582.69-1.451.982.41

Cash distributions per share in year (A$ cents)

06002

Share Price History

PeriodPrice changeBasis

1 year

–3.6%

30 Jun 2025 (A$0.83) → 30 Jun 2026 (A$0.80)

1 year (to mid-Aug 2026)

–35%

Fintel; starting point is the July–August 2025 spike to about A$1.10–1.16

3 years

–54.8%

30 Jun 2023 (A$1.77) → 30 Jun 2026

5 years

–78.4%

30 Jun 2021 (A$3.70) → 30 Jun 2026

Latest

A$0.71

1 Sep 2026 (InvestSMART); trading is very thin, with many zero-volume days

Valuation Multiples

MultipleANOPeers

Market capitalisation

About A$44.5m

—

Enterprise value (incl. leases, less cash)

About A$44.8m

—

P/E (trailing)

29.5x

Not comparable (no listed pure-play peers)

EV/EBITDA

10.9x

Not comparable

EV/Sales

3.4x

Not comparable

P/B

1.23x—

P/NTA

1.65x—

Capital Markets

ItemStatus

Analyst consensus

None. Not covered by any broker (Market Index; Simply Wall St: 0 analysts)

Dividend history

6c unfranked dividend paid 22 Mar 2023 (ex-date 2 Mar 2023); no dividends FY2024–FY2026

Dividend policy

Not formally stated

Capital return

2c per share (A$1.226m) paid 25 Feb 2026

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

No external debt. Lease liabilities: A$543k within 1 year; A$364k in 1–5 years (undiscounted, FY2026 Note 27)

Analyst Conclusions

Management guidance

No formal FY2027 guidance has been issued. The FY2026 Annual Report describes rising global enquiries, regulatory tailwinds from 4-MBC and homosalate restrictions, a possible raw-material stock build, and the start of a home battery storage pilot in FY2027. Consensus forecasts do not exist.

Bull case

  1. Regulatory tailwind is real and dated. EU, UK, China and ASEAN 4-MBC bans and homosalate limits force reformulation in 2026–2028, and zinc oxide is a natural substitute.

  2. The distribution reset has proven operating leverage. US/Canada revenue nearly tripled in two years (A$2.54m to A$7.50m), and gross margin reached 60.8%.

  3. Asset backing limits downside. The price sits at 1.23x book value; there is no debt; and A$4.69m of tax losses shield future profits.

Bear case

  1. The FDA overhang is unresolved and undisclosed in the Annual Report. The US is 57% of revenue; GMP findings and an import alert could curtail sales once warehouse stock is depleted.

  2. Working capital ties up most of the company's value. Inventory of A$11.3m (about 800 days) and cash of A$0.6m leave little room for error, and an inventory write-down would hit equity directly.

  3. Governance and capital allocation. There is no independent board oversight; related-party revenue (Veganic SKN) drove FY2026 sunscreen growth; and the battery project is an unbudgeted pivot far outside the core competency.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
FDA import alert / GMP remediation statusAny timeFormal removal or escalation (warning letter)
2026 AGMAbout November 2026Battery project budget; capital management; board renewal
Q1 FY2027 revenue update (if issued, as in Oct 2025)October 2026US revenue trend after the import alert
H1 FY2027 results26 Feb 2027 (calendar)Inventory, cash, related-party share of revenue
White Sapphire HP and magnesium oxide launches2026–2027First disclosed revenue
Battery pilot facility spendingFY2027Capex size and funding source
US tariff policyOngoingAny removal of the zinc oxide exemption

Analyst verdict

Advance ZincTek is a genuinely profitable, debt-free niche manufacturer with a defensible technical and regulatory position in transparent zinc oxide. It is also a company whose financial profile has failed to compound. FY2026 revenue of A$13.1m is below FY2023 and 27% below the FY2020 peak. Returns on equity and invested capital of about 4% are well below the cost of capital, and the balance sheet ties up more than two years of materials in inventory while holding only A$0.6m of cash.

The FY2025–FY2026 recovery is real but narrow. It rests on a successful US distribution restructure, high gross margins, and a growing but related-party-dependent sunscreen line. The regulatory backdrop, with 4-MBC bans, homosalate limits and TiO2 scrutiny, is the strongest structural tailwind the company has had in a decade, and management correctly identifies it.

Against this, three issues dominate the risk profile. First, the US FDA GMP findings and import alert in late 2025 and early 2026 bear directly on the market that generates 57% of revenue, yet the FY2026 Annual Report omits them from its risk disclosures. That gap is a serious transparency concern. Second, governance is weak: a three-person board without independent directors oversees extensive related-party transactions with entities controlled by a 65% shareholder. Third, the newly announced home battery project is a capital-allocation pivot of uncertain scale and logic for a company of this size.

At A$0.71 the shares trade at about 1.2x book value, 11x EV/EBITDA and about 30x trailing earnings. That valuation neither prices in material growth nor discounts a severe regulatory outcome. With minimal liquidity (free float of about 16%) and no broker coverage. On balance the analyst's stance is neutral with a negative bias, pending clear public disclosure on the FDA matters and a funded, budgeted plan for the battery initiative.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure (start)Prior / other rolesEducation / qualifications

Lev Mizikovsky

Non-Executive Chairman; member of all committees

Director since 10 Apr 2015 (aggregator date)

Founder (July 1989) and Executive Chairman of Tamawood Limited (ASX: TWD); Executive Chairman of SenterpriSys Limited (NSX: SPS) and Veganic SKN Limited; formerly a substantial holder in Lindsay Australia (per FY2023 AR)

FAICD (Fellow of AICD since 1977)

Rade Dudurovic

Non-Executive Director; Chair of Audit Committee; Chair of Nomination & Remuneration Committee

Director since 2 Nov 2011 (aggregator date)

Private equity background in industrial and branded consumer manufacturing and distribution, particularly in Asia; NED of Tamawood (from 31 May 2024), SenterpriSys and Veganic SKN

B.Com (Hons), LLB (Hons), CPA, Senior Fellow FINSIA

Geoff Acton

Managing Director; joint Company Secretary (since 13 Jul 2015); member of Audit and Risk committees

MD since 16 Mar 2016 (aggregator date)

More than 20 years with the Tamawood Group as Director, CFO and Company Secretary; founded Tamawood's Renewable Energy Certificate trading business (2004); NED of Veganic SKN

B.Com, CA, GAICD

Narelle Lynch

Joint Company Secretary

Since 9 Aug 2017

—

Cert Gov Prac

Directors' Remuneration

KMP (AUD)Cash salary/fees FY2026Bonus FY2026Super FY2026LSL FY2026Total FY2026Total FY2025Total FY2024Total FY2023

Lev Mizikovsky (Chair)

00000000

Rade Dudurovic (NED)

62,00400062,00462,00462,40050,000

Geoff Acton (MD)

292,50006,558870299,928299,685288,983265,780

Total KMP

354,50406,558870361,932361,689401,799373,071

Board & Management Changes

DateChangeContext

23 Sep 2022

Linda Barr appointed NED and Audit Chair

Added finance/ICT governance expertise; also a Tamawood and Veganic SKN NED

16 Nov 2022

Laurie Lefcourt retired

—

31 May 2024

Linda Barr resigned

Board reduced to three; Mr Dudurovic assumed Audit Chair

FY2025–FY2026

Lead audit partner rotation (Monaghan → Marti-Warren)

Routine

Major Shareholders

RankHolderShares%
1

Ankla Pty Ltd (Mizikovsky associated)

25,402,08440.53
2

Poltick Pty Ltd (Mizikovsky associated)

15,168,55724.20
3

Kearney Ethical Investments Pty Ltd

5,289,6218.44
4

Mr B M & Mrs M U D Kearney (Kearney Ethical Inv S/F)

1,899,8823.03
5

Citicorp Nominees Pty Ltd (custodian)

1,281,5052.04
6

BNP Paribas Nominees (IB AU Noms Retail)

575,5140.92
7

Mr Edwin Giovanni Diaz

540,1400.86
8

Mr Keith William Kerridge (Australasian Asset Mgmt)

500,0000.80
9

The L and R Super Fund Pty Ltd

472,5620.75
10

Melbourne Corporation of Australia Pty Ltd

400,0000.64
—

Top 20 total

54,510,70486.97

Competitive Landscape

Key Competitors

CompetitorHQCompeting productsRelative positioning vs ANO

BASF SE

Germany

Z-COTE zinc oxide range; organic UV filters

Global scale and formulation support; diversified filter portfolio

Croda International plc

UK

Solaveil mineral UV dispersions

Premium dispersions; strong brand-owner relationships

dsm-firmenich

Switzerland/Netherlands

PARSOL ZX zinc oxide; organic filters

Full UV-filter portfolio

Merck KGaA (EMD Electronics/Surface Solutions)

Germany

Eusolex mineral filters; effect pigments

Effect-pigment overlap with White Sapphire

Kobo Products Inc.

USA (private)

Zinc oxide and TiO2 dispersions

Direct dispersion competitor in US

Sakai Chemical Industry

Japan

Fine zinc oxide (FINEX)

Asian scale; cited by ANO as tariff-exposed

Tayca Corporation

Japan

Micro-particle zinc oxide and TiO2

Asian incumbent

Sumitomo Osaka Cement

Japan

Zinc oxide cosmetic dispersions

Japanese competitor

Grillo-Werke AG

Germany (private)

Pharmaceutical-grade zinc oxide (FDA-listed)

API-grade powder competitor

EverZinc

Belgium (private)

Zinc oxide powders

Commodity-to-specialty zinc oxide

Zochem LLC

USA

Zinc oxide API (FDA 483, Nov 2024, per GKS record)

US domestic API producer

Chinese / Asian low-cost zinc oxide importers

Various

Commodity zinc oxide

Price competition; ANO alleges TGA non-compliance in Australia

Peer Comparison FY2026

MetricAdvance ZincTek (FY2026, Jun)BASF (FY2024, group)Croda (FY2024, group)dsm-firmenich (FY2024, group)

Group revenue

A$13.1m

About €65bn

About £1.6bn

About €12.8bn

Revenue growth

+12.6%

Not segment-comparable

Not segment-comparable

Not segment-comparable

Relevant UV-filter revenue

About A$11.5m (ZinClear)

———

Margin (EBITDA)

31.3% (derived)

Not segment-comparable

Not segment-comparable

Not segment-comparable

R&D intensity

Capitalised development 5.6% of revenue; total not disclosed

Not segment-comparable

Not segment-comparable

Not segment-comparable

“—” = not publicly disclosed.

Recent Developments

There were no layoffs, guidance withdrawals or litigation against ANO in the period beyond the regulatory items noted. Items 14–16 are the most material; the FY2026 Annual Report does not mention them.*

Company Snapshot

$8.5M

Revenue

25

Employees

1997

Founded

Queensland, Australia

Headquarters

SWOT Analysis

Strengths

  • High gross margin. Derived gross margin of 60.8% in FY2026, 58.7% in FY2022–FY2023, shows pricing power (FY2026 AR P&L).
  • No external debt. Lease liabilities only A$870k; net debt including leases A$252k (FY2026 AR).
  • Positive operating cash flow five years running, reaching A$3.35m in FY2026.
  • Regulatory credentials: TGA licence and multiple FDA NDC listings (openFDA; FY2025 AR risk section).
  • Distribution restructuring worked. US/Canada revenue rose from A$2.54m (FY2024) to A$7.50m (FY2026).
  • Tariff exemption: zinc oxide confirmed 100% exempt from US pharmaceutical tariffs (8 Apr 2026).
  • Tax shield: A$4.69m of tax-effected losses mean no cash tax for several years (FY2026 Note 15).

Weaknesses

  • Customer concentration: top three customers 56% of FY2026 revenue (Note 23(b)).
  • Inventory build-up: A$11.3m inventory, about 800 days on raw-material cost; impairment provision up 128% to A$235k (Note 10).
  • Thin cash: A$618k at FY2026 year-end despite A$3.35m OCF.
  • Low returns: ROE 4.2% and ROIC 4.4% in FY2026.
  • Failed product line: White Sapphire revenue down from A$1.02m (FY2024) to A$0.11m (FY2026).
  • Governance: a three-person board with no independent directors and extensive related-party dealings (Tamawood, SenterpriSys, Veganic SKN, Acton-associated entity, Mizikovsky leases).
  • Rising costs: FY2026 corporate costs +174%, consulting +118%, other operating expenses +90%.

Opportunities

  • 4-MBC and homosalate reformulation wave in the EU, UK, China and ASEAN during 2026–2028 (FY2026 MD review).
  • TiO2 reformulation demand in Europe (FY2026 MD review).
  • Adjacent oxides: High Purity White Sapphire (600+ potential customers claimed), magnesium oxide, three new oxides.
  • US regulatory shift toward mineral filters (FDA GRASE framework).
  • European order momentum: euro-denominated receivables rose from A$14k to A$442k at FY2026 year-end (Note 27).
  • Rising enquiries: global enquiries reported "well above" the prior year (20 Jul 2026 release).

Threats

  • FDA GMP findings (Nov 2025) and import alert (Jan 2026) could curtail US sales, 57% of revenue.
  • Low-cost imports pressuring Australian pricing (2 Oct 2025 release).
  • Tariff policy reversal risk (repeated tariff announcements in 2025–2026).
  • Reputational spillover from the Australian SPF controversy and the December 2025 TV allegations.
  • FX: USD/EUR exposure with no hedging; a A$289k FX loss in FY2026.
  • Capital-allocation risk: the battery pilot is a large, unbudgeted project for a company with A$0.6m of cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025"Further Update on Tariffs": zinc oxide exempt from the 10% US tariff on Australian goodsProtects largest market
1–15 Apr 2025Series of Chairman on-market purchases (multiple Appendix 3Y notices)Controlling holder accumulating
9 Apr 2025Application for quotation of securities (employee share issues)Minor dilution
24 Apr 2025Business Update covering Sapphire Matte product issuesWhite Sapphire revenue falls 85% in FY2025
10 Jun 2025"Expected A$2.7 Million Profit Turnaround": PBT about A$1.95m vs FY2024 loss; cash A$525k; no debt; capital management to be raised at AGMEarnings inflection
30 Jun 2025Update on profit turnaroundConfirmation
9 Jul 2025Tariff update: zinc oxide outside proposed 200% US pharmaceutical tariffs; possible US relocation flaggedTariff risk mitigation
21 Jul 2025Response to ASX price and volume query (price about A$1.10, up from A$0.82)Speculative spike; no undisclosed information
29 Aug 2025FY2025 results: revenue A$11.64m (+24.9%), PBT A$2.02m, NPAT A$1.24mReturn to profit
3 Sep 2025ANO states its zinc oxide was not in sunscreens that failed CHOICE SPF testingReputation management amid Australian SPF controversy
26 Sep 2025ANO "optimistic" zinc oxide will be excluded from new US pharmaceutical tariffsTariff risk
2 Oct 2025Q1 FY2026 revenue +26.83% to A$3.01m; complaint about non-compliant zinc oxide imports in AustraliaGrowth momentum; Australian pricing pressure
14 Nov 2025AGM Chair's presentation: Asia/Europe marketing push; White Sapphire HP launch 2026; Perth office closure; ANO will not join Veganic SKN's proceedings against Cancer Council AustraliaStrategy update; related-party litigation context
17 Nov 2025"FDA Inspection Update": per third-party summaries, FDA found GMP compliance issues requiring remediation (share price about A$1.195 at release)Material regulatory event; share price fell about 40% over following months
12 Dec 2025Reputational risk
9 Jan 2026"FDA Update": per third-party summaries, an FDA import alert; shares down about 3% that dayPotential restriction on US imports; resolution status not publicly verified
12–13 Feb 2026Return of capital of 2c per share (about A$1.23–1.3m) announced and updatedCapital management
17 Feb 2026Ex-date for capital return (per Fintel)—
25 Feb 2026Capital return paid (A$1.226m)Cash reduced to about A$0.6m
27 Feb 2026H1 FY2026: revenue A$6.66m (+16.5%), NPAT A$1.16m (+21.4%), EPS 1.84c, NTA 44.49c; no interim dividendStrong half
8 Apr 2026"Zinc Oxide 100% exempt from Pharmaceutical Tariffs"Tariff clarity
5 May 2026Guidance
23 Jun 2026Change in substantial holding (Mizikovsky-associated entities reorganised)Ownership
24 Jun 2026Application for quotation (33,750 employee shares in FY2026)Minor
29 Jun – 4 Aug 2026Continued Chairman on-market purchases at about A$0.80Insider support
20 Jul 2026FY2026 unaudited PBT A$2.294m (+13%); revenue A$13.111m (+12.65%); global enquiries well above prior yearPre-announcement
Aug 2026Share price slides from A$0.805 to A$0.715 (10–11 Aug 2026) on very thin volumeMarket scepticism
31 Aug 2026FY2026 Annual Report and Appendix 4E: audited PBT A$2.247m (vs A$2.294m unaudited), NPAT A$1.509m; home battery storage project announcedResults; strategic pivot

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 12.5 Mn in FY2022 to AUD 13.1 Mn in FY2026.
Advance ZincTek Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue12.513.79.311.613.1
Gross profit = revenue less raw materials7.38.14.56.78

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.